Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data

  title={Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data},
  author={Johan Sundstr{\"o}m and Hisatomi Arima and Mark Woodward and Rod Jackson and Kunal N. Karmali and Donald M. Lloyd‐Jones and Colin Baigent and Jonathan R. Emberson and Kazem Rahimi and Stephen MacMahon and Anushka Patel and Vlado Perkovic and Fiona M Turnbull and Bruce Neal},
  journal={The Lancet},

Figures from this paper

Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study

It is confirmed that the benefit of treatment was substantial only in the high-risk tertile, reaffirming the rationale of treating elevated blood pressure in the setting of all risk factors rather than in isolation.

Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data

A blood pressure-lowering treatment strategy based on predicted cardiovascular risk is more effective than one based on blood pressure levels alone across a range of thresholds and support using cardiovascular risk assessment to guide blood pressure treatment decision-making in moderate- to high-risk individuals, particularly for primary prevention.

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

  • Amanda Larry Ale Folkert W Nigel S Eivind Henry Frank P J Adler Agodoa Algra Asselbergs Beckett Berge Black A. Adler Jiguang Wang
  • Medicine
    The Lancet
  • 2021

The case for absolute cardiovascular risk-based blood pressure-lowering treatment decisions: data from the SPRINT trial

This analysis of the SPRINT trial found that the CVD-risk strategy resulted in a greater number of cardiovascular events avoided per persons treated than the SBP strategy, across a wide range of potential treatment thresholds including below 140 mmHg.

The Blood Pressure Lowering Treatment Trialists’ Collaboration: methodological clarifications of recent reports

The power of pooled analyses of the Blood Pressure Lowering Treatment Trialists’ Collaboration dataset in filling long-standing gaps in knowledge is demonstrated, and some misconceptions regarding the methods underpinning the recent reports are clarified.

Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial

Intensive systolic blood pressure reduction is beneficial for primary prevention of cardiovascular morbidity and mortality in patients without diabetes with more than low cardiac risk (above 10%).

Individualizing treatment choices in the systolic blood pressure intervention trial

Having adverse events has less weight when it comes to therapeutic decisions and antihypertensive therapy intensification is beneficial for the great majority of patients included in the systolic blood pressure intervention trial.

How Much Lowering of Blood Pressure Is Required to Prevent Cardiovascular Disease in Patients With and Without Previous Cardiovascular Disease?

Pharmacologic lowering of blood pressure was effective in preventing major cardiovascular disease events both in people with or without previous cardiovascular disease, which was not modified by their baseline blood pressure level.

Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses

Antihypertensive treatment reduces the risk of mortality and cardiovascular morbidity in people with diabetes mellitus and a systolic blood pressure more than 140 mm Hg, however, further treatment is associated with an increased risk of cardiovascular death, with no observed benefit.



Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

All the classes of blood pressure lowering drugs have a similar effect in reducing CHD events and stroke for a given reduction in blood pressure, indicating that the benefit is explained by blood pressure reduction itself.

Estimating treatment effects for individual patients based on the results of randomised clinical trials

Objectives To predict treatment effects for individual patients based on data from randomised trials, taking rosuvastatin treatment in the primary prevention of cardiovascular disease as an example,

Cost-Effectiveness Analysis of Hypertension Guidelines in South Africa: Absolute Risk Versus Blood Pressure Level

Current guidelinesbased on blood pressure levels are both more expensive and less effective than guidelines based on absolute risk of cardiovascular disease in South Africa, which could free up major resources for other pressing needs, especially in developing countries.

Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.

The combination of trial results in prospectively planned, systematic overviews both reduces random errors and avoids biases and should provide more reliable information about the effects of newer blood-pressure-lowering drugs than would any one study alone.

Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack

This blood-pressure-lowering regimen reduced the risk of stroke among both hypertensive and non-hypertensive individuals with a history of stroke or transient ischaemic attack, irrespective of their blood pressure.

The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives.

The results suggest that over 10 years, treatment would prevent at least one major vascular event among every 10 elderly patients at similar risk to those enrolled in the trials.

Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

There are similar blood pressure-dependent effects of ACEI and ARB for the risks of stroke, CHD and heart failure and for ACEI, but not ARB, there is evidence ofBlood pressure-independent effects on the risk of major coronary disease events.

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study

Changing to absolute risk-based cardiovascular disease prevention is highly recommended for reducing health sector spending, but the Australian Government must also consider measures to reduce the cost of statin drugs, over and above the legislated price cuts of November 2010.